Thrombin Receptor Antagonist in the Secondary prevention of atherothrombotic ischaemic events (TRA2P)

It evaluates the safety and efficacy of SCH 530348 (Thrombin Receptor Antagonist) in addition to standard of care in subjects with a history of atherosclerotic disease(Secondary Prevention of Atherothrombotic Ischaemic Events).